Medincell Drops 4.25% in Late Afternoon, Shares Lose Ground
Medincell stock falls by 4.25% to €26.58, erasing the week's gains and intensifying a three-month correction. The stock is now close to its 20-day moving average, while key stock market events for the year remain anticipated.
The daily decline of 4.25% brings Medincell to €26.58. Over three months, the decline has intensified with a drop of 26.82%, while the annual performance remains positive at 64.28%. Technically, the price is immediately near its 20-day moving average (€26.47), indicating some short-term fragility. The monthly volatility, established at 16.92%, confirms an unstable dynamic. The stock still trades above its long-term 200-day average (€21.88), maintaining a balance between support at €23.90 and resistance at €29.20.
Analyst Upgrade and Key Dates
Free · Every morning
Technical market signals, before the opening bell.
Bullish and bearish momentum, analyst changes, stocks to watch — automatically computed from Euronext data.
✓ Before 9 AM every morning✓ Euronext data✓ AI-powered analysis
Almost there! Check your inbox.
A confirmation email has been sent. Click the link to confirm your subscription.
An error occurred.
Indicative data. No investment advice. Unsubscribe at any time.
Oddo BHF raised its price target on January 16 from €27.00 to €34.00 while maintaining its outperformance recommendation. This adjustment suggests a potential upside of 28% from the current price. The stock market calendar includes several key dates: the annual results for the fiscal year 2025-2026 will be unveiled on June 16, 2026, followed by the general meeting on September 10 and the results for the first half of 2026-2027 on December 8.
We are pleased with the company’s growth and momentum.
Total income €14,1 million; Revenues €11,6 million (+35 %); UZEDY® royalties €4,2 million; Operating result €(6,6) million (improved 13 % year-over-year); Net result €(16 078) thousand; Cash and low-risk financial investments €53,5 million (incl. €49,8 million cash and €3,7 million low-risk investments); Net financial debt €17 629 thousand; NDA for Olanzapine LAI submitted to FDA on December 9, 2025; AbbVie partnership advancing with regulatory package expected in 2026.
Risks mentioned
Foreign exchange risk: weakness of USD vs EUR impacted revenues and generated ~€1 million FX losses
Dependency on partner commercialization (Teva) for UZEDY® royalties and sales forecasts
Regulatory risk: approvals (e.g., Olanzapine LAI) and acceptance for review uncertain
Financial volatility linked to fair value revaluation of EIB BSA warrants (non-cash €6,8 million impact)
Opportunities identified
Olanzapine LAI: NDA submitted and potential launch could be a major growth catalyst
UZEDY®: upward revision of 2025 net sales forecast by Teva (from $160 million to $190-200 million)
AbbVie partnership: first program advancing toward first-in-human trials (regulatory package expected 2026)
Gates Foundation financing: new $3 million envelope to advance mdc-STM malaria program
Expanded geographic approvals (Canada, South Korea) supporting broader commercialization
The information presented in this article is provided for informational purposes only and does not constitute an investment recommendation, an incentive to buy or sell a financial asset, or investment advice. Readers are invited to conduct their own research before making any decision.
Investments in the stock market involve risks, including the risk of capital loss. Past performance of an asset or market is no guarantee of future results. Any investment decision should be made taking into account your personal financial situation, objectives and risk tolerance.
